Earlier this year, Novartis instituted major corporate changes, replacing CEO David Epstein and dividing its pharmaceutical arm in two, with one division focusing on cancer research and the other on drug development. In a statement, the company said they reallocated researchers from the cell and gene therapies unit “as part of a natural evolution of our internal organizational design. An isolated Unit worked well under our prior Pharma Division structure, but with a new integrated development model, we can efficiently advance our work on CAR-T as part of our focus in immuno-oncology by reintegrating the functions,” according to Endpoint News.
“Novartis is committed to the ongoing development of CAR-T therapies” and will move forward with plans to submit CTL019 for approval later next year, the statement continued. In addition, dissolving the unit will not impact a collaboration between Novartis and the University of Pennsylvania. “Novartis and Penn have an exclusive global collaboration to research, develop, and commercialize CAR-T cell therapies for the investigational treatment of cancers. We continue to work with Penn under the terms of our agreement and look forward to advancing CAR-T therapies.”